SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines

被引:6
|
作者
Paciello, Ida [1 ]
Maccari, Giuseppe [2 ]
Pierleoni, Giulio [1 ,3 ]
Perrone, Federica [1 ,3 ]
Realini, Giulia [1 ]
Troisi, Marco [1 ]
Anichini, Gabriele [4 ]
Cusi, Maria Grazia [4 ]
Rappuoli, Rino [3 ,5 ]
Andreano, Emanuele [1 ]
机构
[1] Fdn Toscana Life Sci, Monoclonal Antibody Discovery MAD Lab, Siena, Italy
[2] Fdn Toscana Life Sci, Data Sci Hlth DaScH Lab, Siena, Italy
[3] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy
[4] Univ Siena, Dept Med Biotechnol, Virol Unit, Siena, Italy
[5] Fdn Biotecnopolo Siena, Siena, Italy
基金
欧洲研究理事会;
关键词
ANTIBODIES;
D O I
10.1126/sciimmunol.adp9279
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
    Chemaitelly, Hiam
    Coyle, Peter
    Ben Kacem, Mohamed Ali
    Ayoub, Houssein H.
    Tang, Patrick
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Al Thani, Asmaa A.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed Ghaith
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    JOURNAL OF TRAVEL MEDICINE, 2024, 31 (04)
  • [12] Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
    Raddad, Laith
    Chemaitelly, Hiam
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [13] Genetic variability of the SARS-CoV-2 JN.1 lineage
    Scarpa, Fabio
    Ciccozzi, Massimo
    PATHOGENS AND GLOBAL HEALTH, 2024, 118 (03) : 277 - 279
  • [14] T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots
    Tian, Jinmin
    Shang, Bingli
    Zhang, Jianing
    Guo, Yuanyuan
    Li, Min
    Hu, Yuechao
    Bai, Dan
    She, Junying
    Han, Yang
    Guo, Peipei
    Huang, Mengkun
    Wang, Yalan
    Liu, Maoshun
    Zhang, Jie
    Ye, Beiwei
    Guo, Yaxin
    Yang, Mengjie
    Lin, Ying
    Zhang, Ting
    Sun, Xin
    Yuan, Xiaoju
    Zhang, Danni
    Xu, Ziqian
    Chai, Yan
    Qi, Jianxun
    Liu, Kefang
    Tan, Shuguang
    Zhao, Yingze
    Zhou, Jikun
    Song, Rui
    Gao, George F.
    Liu, Jun
    NATURE IMMUNOLOGY, 2025, 26 (02) : 265 - 278
  • [15] Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants
    Yang, Haonan
    Guo, Huimin
    Wang, Aojie
    Cao, Liwei
    Fan, Qing
    Jiang, Jie
    Wang, Miao
    Lin, Lin
    Ge, Xiangyang
    Wang, Haiyan
    Zhang, Runze
    Liao, Ming
    Yan, Renhong
    Ju, Bin
    Zhang, Zheng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [16] The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
    Lu, Yishan
    Ao, Danyi
    He, Xuemei
    Wei, Xiawei
    MEDCOMM, 2024, 5 (08):
  • [17] Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion
    Li, Pei
    Liu, Yajie
    Faraone, Julia N.
    Hsu, Cheng Chih
    Chamblee, Michelle
    Zheng, Yi-Min
    Carlin, Claire
    Bednash, Joseph S.
    Horowitz, Jeffrey C.
    Mallampalli, Rama K.
    Saif, Linda J.
    Oltz, Eugene M.
    Jones, Daniel
    Li, Jianrong
    Gumina, Richard J.
    Liu, Shan-Lu
    MBIO, 2024, 15 (05):
  • [18] JN.1: ongoing considerations of the shifting landscape of SARS-CoV-2 variants
    Basu, Soumya
    Kayal, Titirsha
    Patro, Ponoop Prasad
    Patnaik, Amit
    FUTURE MICROBIOLOGY, 2024, 19 (07) : 559 - 562
  • [19] Concerns regarding SARS-CoV-2 JN.1 mutations should be raised
    Miah Roney
    A. K. M. Moyeenul Huq
    Mohd Fadhlizil Fasihi Mohd Aluwi
    Bulletin of the National Research Centre, 48 (1)
  • [20] Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra
    Karyakarte, Rajesh P.
    Das, Rashmita
    Rajmane, Mansi, V
    Dudhate, Sonali
    Agarasen, Jeanne
    Pillai, Praveena
    Chandankhede, Priyanka M.
    Labhshetwar, Rutika S.
    Gadiyal, Yogita
    Kulkarni, Preeti P.
    Nizarudeen, Safanah
    Yanamandra, Sushma
    Taji, Nyabom
    Joshi, Suvarna
    Potdar, Varsha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)